This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

An Open-Label, Flexible-Dose Study of Olanzapine in the Treatment of Trichotillomania

Rege S. Stewart, MD; and Vicki A. Nejtek, PhD

Published: January 15, 2003

Article Abstract

Background: Thus far, only selective serotonin reuptake inhibitors have been systematically studied in the treatment of trichotillomania, and the results are conflicting. This open-label study is the first to systematically evaluate an atypical neuroleptic, olanzapine, as a monotherapy in the treatment of trichotillomania.

Method: Twenty-one patients were screened and 18 patients were enrolled in a 3-month open-label study of olanzapine for trichotillomania (diagnosis based on modified DSM-IV criteria). Patients with comorbid psychiatric disorders or on treatment with psychoactive medication were excluded. Olanzapine was titrated gradually in 2.5-mg/week increments up to a maximum dose of 10 mg/day.

Results: Seventeen patients who completed at least 1 week of olanzapine treatment were evaluated. Hair pulling, as measured by the Massachusetts General Hospital Hairpulling Scale, decreased by 66% from baseline (p<=.001), and mean scores on the Hamilton Rating Scale for Anxiety decreased by 63% (p<=.05). Clinical Global Impressions scale scores also revealed significant improvement as a whole (p<=.001), with 4 patients having complete symptom remission at the end of the study period.

Conclusion: Findings suggest that olanzapine may be an effective monotherapy for trichotillomania.

Volume: 64

Quick Links: Psychiatry

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...